Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of October 2026
Becky Berkman @Becky Berkman
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Qualitative fundamental analysis

Market capitalization:

$8,319,988talents

Virtual portfolio value:

$5,330,875talents

Net overall return per annum:

18.65%

AYA current rank order:

#6

Asset investment philosophy:
Becky Berkman trades U.S. stocks with the top #151 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 19,227 +2,108.33% $145,933
BQ Boqii Holding Limited American Depositary Shares representing Class A Ordinary Shares $0.36 $3.36 40,069 +833.33% $120,207
BQ Boqii Holding Limited Class A Ordinary Shares $0.36 $3.36 40,069 +833.33% $120,207
SXTP 60 Degrees Pharmaceuticals Inc. Common Stock $0.15 $1.34 96,260 +793.33% $114,549
VATE INNOVATE Corp. Common Stock $0.53 $4.14 27,243 +681.13% $98,347
ZJYL JIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares $24.06 $248.05 392 +930.96% $87,804
SSNT SilverSun Technologies Inc. Common Stock $18.59 $130.48 667 +601.88% $74,631
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 2,857 +660.87% $65,140
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 1,010 +589.24% $41,481
FIVN Five9 Inc. Common Stock $16.31 $110.10 431 +575.05% $40,423
Sum $908,722

Top 10 current stock portfolio positions as of October 2026Strategy

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@Andy Yeh Alpha

Blog+More

Partisanship matters more than the socioeconomic influence of the rich and elite interest groups.

John Fourier

2019-08-26 11:30:00 Monday ET

Partisanship matters more than the socioeconomic influence of the rich and elite interest groups.

Partisanship matters more than the socioeconomic influence of the rich and elite interest groups. This new trend emerges from the recent empirical analysis

+See More

President Trump is open to extending the March 2019 deadline for raising tariffs on Chinese imports.

Peter Prince

2019-02-15 11:33:00 Friday ET

President Trump is open to extending the March 2019 deadline for raising tariffs on Chinese imports.

President Trump is open to extending the March 2019 deadline for raising tariffs on Chinese imports if both sides are close to mutual agreement. These bilat

+See More

Peter Schuck analyzes U.S. government failures and structural problems in light of both institutions and incentives.

Dan Rochefort

2023-04-28 16:38:00 Friday ET

Peter Schuck analyzes U.S. government failures and structural problems in light of both institutions and incentives.

Peter Schuck analyzes U.S. government failures and structural problems in light of both institutions and incentives. Peter Schuck (2015)   Why

+See More

Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor.

Apple Boston

2018-08-11 14:35:00 Saturday ET

Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor.

The Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor, Andrew Brunson, in Turkey

+See More

The May administration needs to seek a fresh fallback option for Halloween Brexit.

Peter Prince

2019-05-15 12:32:00 Wednesday ET

The May administration needs to seek a fresh fallback option for Halloween Brexit.

The May administration needs to seek a fresh fallback option for Halloween Brexit. After the House of Commons rejects Brexit proposals from the May administ

+See More

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

Monica McNeil

2025-10-31 12:26:00 Friday ET

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi

+See More